Bristol immune drug shows promise in three cancers

CHICAGO (Reuters) – An experimental Bristol-Myers Squibb drug helped shrink tumors in patients with advanced melanoma, kidney and lung cancers in a preliminary trial, raising hopes for yet another drug that can wake up the immune system and train it to attack cancer cells. Early-stage tests of the drug BMS-936558, known as an anti-PD-1 treatment, showed it was relatively safe and shrank tumors in three of the five cancer types studied, the team reported at the American Society of Clinical Oncology (ASCO) meeting on Saturday and published online in the New England Journal of Medicine. …

Hospitals fight drug scarcity, fear patients harmed

A bottle of prescription medication rests on a counter at a pharmacy in New YorkWASHINGTON (Reuters) – At the Henry Ford Hospital in Detroit, pharmacists are using old-fashioned paper spreadsheets to track their stock of drugs in short supply – a task that takes several hours each day. Most of the hospital's medicines – with usage estimated at $100 million a year – are tracked by automated systems that allow for quick reorders when the supply runs low. But these automated systems, designed to help the hospital avoid purchases and storage costs of unused pills and vials, do not work if it is uncertain when the next batch of drugs will come in. …

Cancer Drug Shrinks Tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists called the research encouraging, but more study is needed to know whether the drug will prolong life for cancer patients.

1 117 118 119 120 121 124